The smokeable (cigarettes and cigars) segment defended earnings through pricing and imported-cigarette tax and duty refunds, even as shipments declined and the discount mix widened. Adjusted operating company income rose 2.4% YoY to $3.018 billion, with adjusted margin expanding 0.3 percentage points to 64.8%. With smokeable products accounting for the overwhelming share of the $6.111 billion (+0.1%) in total net revenues, this segment's earnings defense sat at the center of the company's overall numbers.

On a first-half basis, adjusted diluted EPS grew 4.9% to $2.80, and the company returned about $3.9 billion to shareholders through roughly $3.6 billion in dividends and $335 million in share repurchases. On the smoke-free front, Helix expanded on! PLUS to 120,000 stores nationwide and flagged a Q3 nationwide rollout along with additional flavor and nicotine-strength line-ups in Q4, sustaining the medium-term transition narrative.

The market's key metric, adjusted diluted EPS, came in at $1.48, up 2.8% from $1.44 a year earlier but two cents short of the $1.50 analyst estimate. Reported diluted EPS was $1.37, reflecting charges tied to tobacco- and health-related litigation, costs from consolidating U.S. smokeless tobacco manufacturing (UST facility integration), and one-off items related to ABI.

Domestic cigarette shipments fell 3.2%, and adjusting for inventory changes the decline is estimated at roughly 4.5%. Marlboro's retail share slipped 1.5 percentage points YoY to 39.5%, while the industry's discount-cigarette share rose to 33.8%, signaling a rotation of adult nicotine users with pressured discretionary income away from premium brands toward discount alternatives. The oral tobacco segment saw net revenue fall 5.3% and adjusted OI decline 8.0%, and on!'s share of the nicotine pouch category was also lower YoY, underscoring ongoing competitive intensity.

Management said it executed on its year-start priorities in Q2 as well: expanding the smoke-free portfolio, strengthening the traditional tobacco business, and returning capital to shareholders. Pointing to first-half adjusted earnings growth and large-scale cash returns as evidence of confidence in the annual plan, management lifted only the lower bound of full-year adjusted diluted EPS guidance, narrowing the range. From the market's perspective, this leaves considerable room to read the move as a modest tightening that reinforces the floor rather than an aggressive upward revision that also lifts the ceiling.

Management noted that the guidance already incorporates an e-cigarette industry slowdown, macroeconomic uncertainty for adult nicotine consumers, contract-manufacturing investment, no return of NJOY ACE to the market in 2026, reinvestment of cost savings, and vision-related investments. For the second half, management expects tobacco import-related benefits to be larger than in the first half, though some Q2 pull-forward effects mean 3Q and 4Q will be more evenly distributed. Capex guidance was raised on investments tied to UST plant consolidation, a point also disclosed that sharpens near-term cash-outlay pressure.

With adjusted EPS below expectations, cigarette shipment declines, lower Marlboro share, and oral-segment profit weakness all hitting at once, the tone tilted more toward concerns over demand softening and mix deterioration than the stability narrative of a dividend growth name. Raising the lower end of guidance is positive in direction, but with no lift to the upper bound, the NJOY ACE gap persisting, and capex stepping up, the combination reawakened concerns about near-term cost and growth shortfalls, translating into after-hours selling pressure.